BRPI0519026A2 - arranjos de antÍgeno de il-15 e usos dos mesmos - Google Patents

arranjos de antÍgeno de il-15 e usos dos mesmos

Info

Publication number
BRPI0519026A2
BRPI0519026A2 BRPI0519026-6A BRPI0519026A BRPI0519026A2 BR PI0519026 A2 BRPI0519026 A2 BR PI0519026A2 BR PI0519026 A BRPI0519026 A BR PI0519026A BR PI0519026 A2 BRPI0519026 A2 BR PI0519026A2
Authority
BR
Brazil
Prior art keywords
composition
antigen
provides
arrangements
mutein
Prior art date
Application number
BRPI0519026-6A
Other languages
English (en)
Inventor
Patrik Maurer
Martin Bachmann
Yu Zou
Alain Tissot
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of BRPI0519026A2 publication Critical patent/BRPI0519026A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ARRANJOS DE ANTÍGENO DE IL-15 E USOS DOS MESMOS. A presente invenção refere-se aos campos da biologia molecular, virologia, imunologia e medicina. A invenção fornece uma composição compreendendo um arranjo de antígeno ordenado e repetitivo, em que o antígeno é uma proteína de IL-15, uma muteina de IL-15 ou um fragmento de IL-1 5. Mais especificamente, a invenção fornece uma composição compreendendo uma partícula semelhante a vírus, e pelo menos uma proteína de IL-15, muteina de IL-15 ou pelo menos um fragmento de IL-15 ligante à esta. A invenção também fornece um processo para produzir a composição. As composições da invenção são úteis na produção de vacinas para o tratamento de doenças inflamatórias e auto-imunes crônicas. A composição da invenção eficientemente induz respostas imunes, em particular respostas de anticorpo. Além disso, as composições da invenção são particularmente úteis para induzir eficientemente respostas imunes auto-específicas dentro do contexto indicado.
BRPI0519026-6A 2004-12-13 2005-12-12 arranjos de antÍgeno de il-15 e usos dos mesmos BRPI0519026A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63517904P 2004-12-13 2004-12-13
PCT/EP2005/056680 WO2006063974A2 (en) 2004-12-13 2005-12-12 Il-15 antigen arrays and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0519026A2 true BRPI0519026A2 (pt) 2008-12-23

Family

ID=36192618

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519026-6A BRPI0519026A2 (pt) 2004-12-13 2005-12-12 arranjos de antÍgeno de il-15 e usos dos mesmos

Country Status (14)

Country Link
US (1) US20090123414A1 (pt)
EP (1) EP1830875A2 (pt)
JP (1) JP2008523132A (pt)
KR (1) KR20070089186A (pt)
CN (1) CN101076352A (pt)
AU (1) AU2005315658A1 (pt)
BR (1) BRPI0519026A2 (pt)
CA (1) CA2590778A1 (pt)
IL (1) IL183457A0 (pt)
MX (1) MX2007006832A (pt)
NZ (1) NZ555590A (pt)
RU (1) RU2007126553A (pt)
WO (1) WO2006063974A2 (pt)
ZA (1) ZA200704908B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
EP1524994B1 (en) * 2002-07-19 2011-04-27 Cytos Biotechnology AG Vaccine compositions containing amyloid beta1-6 antigen arrays
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP3851459B1 (en) 2010-09-21 2024-05-01 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
EP2630158B1 (en) * 2010-10-22 2018-12-12 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
HK1200849A1 (en) 2011-12-22 2015-08-14 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US10548957B2 (en) 2012-09-28 2020-02-04 Dana-Farber Cancer Institute, Inc. Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
KR102762243B1 (ko) 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
US10526376B2 (en) 2015-01-15 2020-01-07 University Of Copenhagen Virus-like particle with efficient epitope display
GB201503500D0 (en) * 2015-03-02 2015-04-15 Ucl Business Plc Cell
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
DK3368068T3 (da) 2015-10-30 2021-02-22 Univ Copenhagen Viruslignende partikler med effektiv epitopdisplay
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
EP3529263B1 (en) 2016-10-21 2025-08-06 Altor BioScience Corporation Multimeric il-15-based molecules
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
EP3759129A1 (en) 2018-02-28 2021-01-06 Pfizer Inc Il-15 variants and uses thereof
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
EP3781596A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
EP3781597A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
BR112021006783A2 (pt) 2018-10-12 2021-07-13 Xencor, Inc. proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer.
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2021233260A1 (zh) * 2020-05-18 2021-11-25 先声（上海）医药有限公司 人il-15突变体及其用途
WO2024263698A1 (en) * 2023-06-22 2024-12-26 Memorial Sloan-Kettering Cancer Center Anti-pd-l1 immunoglobulin-related compositions comprising il-15-il-15ra fusion polypeptides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1359312A (fr) * 1963-03-14 1964-04-24 Siderurgie Fse Inst Rech Perfectionnements aux procédés de dégazage des métaux en fusion
US3700429A (en) * 1970-01-05 1972-10-24 Allegheny Ludlum Steel Method of controlling vacuum decarburization
JPS6173817A (ja) * 1984-09-18 1986-04-16 Sumitomo Electric Ind Ltd 溶鋼制御精錬法および精錬装置
US4918705A (en) * 1989-07-06 1990-04-17 General Electric Company Furnace enclosure having a clear viewpath
CA2288129A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
PL217752B1 (pl) * 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
ES2320638T3 (es) * 2001-11-07 2009-05-27 Cytos Biotechnology Ag Disposicion ordenada de antigenos il-5, il-13 o eotasina, para el tratamiento de enfermedades alergicas con un componente eosinofilico.
KR20050044314A (ko) * 2001-11-07 2005-05-12 사이토스 바이오테크놀로지 아게 뼈 질환 치료용 항원 어레이
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
US20040076645A1 (en) * 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates

Also Published As

Publication number Publication date
AU2005315658A1 (en) 2006-06-22
NZ555590A (en) 2009-07-31
US20090123414A1 (en) 2009-05-14
WO2006063974A3 (en) 2006-08-17
IL183457A0 (en) 2007-09-20
KR20070089186A (ko) 2007-08-30
JP2008523132A (ja) 2008-07-03
WO2006063974A2 (en) 2006-06-22
CN101076352A (zh) 2007-11-21
CA2590778A1 (en) 2006-06-22
EP1830875A2 (en) 2007-09-12
ZA200704908B (en) 2008-10-29
MX2007006832A (es) 2007-08-07
RU2007126553A (ru) 2009-01-20

Similar Documents

Publication Publication Date Title
BRPI0519026A2 (pt) arranjos de antÍgeno de il-15 e usos dos mesmos
BR0213950A (pt) Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
BRPI0511751A (pt) usos médicos de conjugados veìculos de peptìdeos de tnf não-humano
BRPI0516775A (pt) ensaios de polipeptìdeo de antìgeno de inibidor gástrico (gip) e seus usos
DE60230963D1 (de) Molekulare anordnung von amyloid beta antigenen
ECSP055551A (es) Composiciones de vacunas que contienen arreglos de antígeno amiloide beta 1-6
DE60329106D1 (de) Ghrelin-träger-konjugate
BR0213941A (pt) Arranjos de antìgeno para o tratamento de doença óssea
ES2154738T3 (es) Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
HRP20140419T1 (hr) Molekule za vezanje koje mogu neutralizirati virus bjesnoä†e i njihova uporaba
BRPI0620946A8 (pt) anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
ATE494910T1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
BRPI0516953A (pt) partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico
CY1112895T1 (el) Μεταβολη της ισορροπιας τη1/τη2 στα διαχωρισμενα αντιγριπικα εμβολια με ανοσοενισχυτικα
WO2006037787A3 (en) Vlp-antigen conjugates and their uses as vaccines
NO20012135L (no) Forsterkede vaksiner
BRPI0507002A (pt) conjugados veìculos de grelina
MXPA04003901A (es) Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.
WO2003059386A3 (en) Prion protein carrier-conjugates
MXPA04003900A (es) Disposiciones de antigenos para el tratamiento de enfermedades oseas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.